Composition using urine sample for diagnosis of kidney disease
The composition and kit for diagnosing kidney disease using amphiregulin detection in urine samples address the lack of early diagnosis methods, offering non-invasive and effective tools for kidney disease detection and end-stage renal failure prediction.
Patent Information
- Application Number
- JP2024111723
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-04-10
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods lack effective and non-invasive means for early diagnosis of kidney diseases and prediction of progression to end-stage renal failure.
A composition and kit for diagnosing kidney disease using a urine sample by detecting amphiregulin or its mRNA, with methods involving amphiregulin-specific antibodies or aptamers, and analytical techniques like ELISA and PCR to measure amphiregulin levels.
Enables early and easy diagnosis of kidney disease and prediction of end-stage renal failure through non-invasive urine analysis, providing accurate markers for kidney function and fibrosis progression.
Smart Images

Figure 2024160230000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for diagnosing kidney disease using a urine sample, and more specifically, to a urine test composition and kit for diagnosing kidney disease, which contain an agent for specifically detecting amphiregulin from a urine sample, and a method for diagnosing kidney disease using the composition. [Background technology]
[0002] In recent years, the incidence of lifestyle-related diseases such as hypertension and diabetes has increased due to major changes in lifestyle, including dietary habits, and the aging population, and this has led to an increased risk of kidney disease and even kidney failure.
[0003] The kidney is an important organ in maintaining the homeostasis of the internal environment by excreting waste products, regulating fluid, electrolyte and acid-base balance, etc. The kidney controls the concentration of various compounds in the blood, such as hydrogen, sodium, potassium and silicon, and excretes waste products in urine. Any reduction in kidney function can interfere with the body's ability to adequately remove metabolic products from the blood, disrupting the body's electrolyte balance. The reduction or failure of kidney function can be fatal in its symptoms.
[0004] Chronic renal failure is a state in which renal function is gradually and unidirectionally (irreversibly) decreased, making it impossible to maintain homeostasis. Chronic renal failure is known to occur due to diabetic renal failure, chronic glomerulonephritis, malignant nephrosclerosis, polycystic kidney disease, and other conditions. All kidney diseases are accompanied by renal fibrosis, eventually leading to end-stage renal failure. In particular, chronic renal function decline is closely related to the progression of renal fibrosis, and it is believed that the progression of chronic renal failure can be inhibited by inhibiting the progression of fibrosis.
[0005] In general, renal fibrosis is accompanied by inflammatory reactions due to endothelial cell injury, and ultimately, excessive production of extracellular matrix (ECM) leads to the development of fibrosis. For example, in glomerulosclerosis, protoglomerular endothelial cell injury leads to the secretion of cytokines such as chemokines and growth factors, and monocytes and macrophages induce inflammatory reactions. Then, activation, proliferation, and transformation of mesangial cells occur, and excessive production of extracellular matrix in extracellular matrix-producing cells such as mesangial cells leads to fibrosis, which then leads to glomerulosclerosis.
[0006] In particular, diabetic renal failure is the biggest cause of chronic renal failure and is one of the serious complications of diabetes. A characteristic of diabetic renal failure is the proliferation of glomerular mesangial, which is associated with increased accumulation of ECM proteins, mainly type I and type IV collagen, fibronectin, and laminin (Verena Klemis et al., Kidney International (2017) 91, 1374-1385).
[0007] When chronic renal failure worsens and progresses to the point where the kidneys can no longer function, it leads to end-stage renal disease (ESRD). Once ESRD is reached, recovery is impossible, and patients with ESRD must either undergo dialysis (hemodialysis or peritoneal dialysis) to restore kidney function, or receive a new kidney via transplant.
[0008] Meanwhile, it is known that amphiregulin binds to the epidermal growth factor receptor, activates the epidermal cell receptor pathway (EGFR pathway), and is involved in cell proliferation. It has been disclosed that amphiregulin expression can be inhibited by amphiregulin-specific siRNA, which has a therapeutic effect on certain types of breast cancer (Cancer Res 2008;68:225-2265). It has also been reported that cell invasion in inflammatory breast cancer can be suppressed by using shRNA against amphiregulin (J Cell Physiol 2011 226(10):2691-2701), and that suppression of amphiregulin expression using amphiregulin-specific shRNA suppresses pulmonary artery remodeling in mice exposed to cigarette smoke. It has been reported that amphiregulin is related to airway smooth muscle (ASM) hyperplasia and angiogenesis, in particular promoting airway remodeling in asthmatic patients, and that amphiregulin is involved in tissue remodeling due to acute asthma, together with epidermal growth factor (EGF), which is oversecreted.
[0009] Known diagnostic methods using amphiregulin include a method for diagnosing chorioamnionitis (WO2008-029664) and a method for diagnosing inflammatory diseases (US2006-0286586); however, there have been no studies to date on the use of amphiregulin to diagnose kidney diseases.
[0010] Therefore, the inventors recognized the importance of early diagnosis because recovery is difficult once kidney disease has progressed to a severe stage, and while searching for a method for easily diagnosing kidney disease from urine that can be collected without invasive procedures, they confirmed that kidney disease can be easily diagnosed and the presence or absence of progression of end-stage renal failure can be predicted by checking the amphiregulin concentration in urine, thereby completing the present invention. Summary of the Invention
[0011] An object of the present invention is to provide a renal disease diagnostic composition and kit that can diagnose renal disease early and easily from a urine sample, a method for providing information for diagnosis, and a method for providing information for predicting the possibility of progression of end-stage renal failure.
[0012] In order to achieve the above object, the present invention provides a composition for diagnosing kidney diseases, which comprises an agent that specifically detects amphiregulin or its mRNA.
[0013] The present invention also provides a kit for diagnosing kidney disease, comprising the composition.
[0014] The present invention also provides a method for providing information for diagnosing kidney disease, comprising the steps of: (a) obtaining a urine sample from an individual; (b) detecting amphiregulin in a urine sample; and (c) determining that the individual has kidney disease if amphiregulin detected in the urine sample is greater than or equal to 5 pg / mgCr.
[0015] The present invention also provides an information providing method for predicting the likelihood of progression to end stage renal disease, comprising the steps of: (a) collecting a urine sample from a patient suffering from kidney disease; (b) measuring the amount of amphiregulin in a urine sample; and (c) determining that the patient is at risk of progressing to end stage renal failure if the measured amount of amphiregulin is 30 pg / mgCr or greater.
[0016] The present invention also provides the use of a composition comprising an agent that specifically detects amphiregulin for diagnosing kidney diseases.
[0017] The present invention also provides an use for producing a reagent for diagnosing kidney disease, comprising an agent capable of specifically detecting amphiregulin.
[0018] The present invention also provides a method for diagnosing kidney disease, comprising the steps of: (a) obtaining a urine sample from an individual; (b) detecting amphiregulin in a urine sample; and (c) determining that the individual has kidney disease if amphiregulin detected in the urine sample is greater than or equal to 5 pg / mgCr.
[0019] The present invention also provides a method for predicting the likelihood of progression to end-stage renal disease, comprising the steps of: (a) collecting a urine sample from a patient suffering from kidney disease; (b) measuring the amount of amphiregulin in a urine sample; and (c) determining that the patient is at risk of progressing to end stage renal failure if the measured amount of amphiregulin is 30 pg / mgCr or greater. [Brief description of the drawings]
[0020] [Figure 1] The results show the expression rates of amphiregulin mRNA in kidney and lung tissues of normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0021] [Diagram 2] The results show the mRNA expression rate of collagen 1 in kidney and lung tissues of normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0022] [Diagram 3] The results show the expression rate of fibronectin mRNA in kidney and lung tissues of normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0023] [Figure 4] The results show the amphiregulin / creatinine ratio measured by ELISA in the urine of normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0024] [Diagram 5]The albumin / creatinine ratio was measured by ELISA in urine from normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0025] [Figure 6A] These are the results of H&E or MT staining of lung tissues from normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0026] [Figure 6B] These are the results of H&E or MT staining of kidney tissues from normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0027] [Figure 7] 1 is a graph showing blood urea nitrogen in serum samples from normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0028] [Figure 8] 1 is a graph showing creatinine values in serum samples from normal animals (Normal) and an animal model of pulmonary fibrosis (BLM).
[0029] [Figure 9] FIG. 1 is a graph comparing amphiregulin concentrations in serum (A) and urine (B) of patients who underwent kidney tissue examination and were diagnosed with IgA nephropathy or diabetic nephropathy, whose kidney pathology findings showed severe minor glomerular changes.
[0030] [Figure 10]FIG. 10 is a graph comparing urinary amphiregulin concentrations according to the severity of histological findings associated with renal fibrosis (A: interstitial fibrosis, B: intimal thickening, C: tubular atrophy, C: mesangial expansion) for the patient groups in FIG.
[0031] [Figure 11] FIG. 11A shows the results of an analysis of amphiregulin concentrations in plasma from a normal control group and a type 2 diabetes patient group, FIG. 11B shows the results of an analysis of amphiregulin concentrations in plasma from a type 2 diabetes patient group, which was additionally divided into three groups based on the degree of albuminuria, FIG. 11C shows the results of an analysis of amphiregulin concentrations in urine from a normal control group and a type 2 diabetes patient group, and FIG. 11D shows the results of an analysis of amphiregulin concentrations in urine from a type 2 diabetes patient group, which was additionally divided into three groups based on the degree of albuminuria.
[0032] [Figure 12] These are the results of confirming the amount of amphiregulin in urine according to the stage of chronic kidney disease in a patient group who underwent kidney tissue testing.
[0033] [Figure 13] This is a Kaplan-Meier survival curve graph comparing the progression of end-stage renal disease according to amphiregulin concentration in a group of patients who underwent kidney tissue testing. Urinary amphiregulin concentrations were divided into three groups according to tertiles, and named T1, T2, and T3 in ascending order of concentration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.
[0035] In the present invention, kidney tissue tests were performed on patients suspected of kidney damage due to various diseases, and it was confirmed that amphiregulin in the urine of this patient group reflects the degree of fibrosis inside the kidney.
[0036] Therefore, in one aspect, the present invention relates to a composition for diagnosing kidney diseases, which comprises an agent that specifically detects amphiregulin or its mRNA.
[0037] In the present invention, the agent can be characterized by specifically detecting amphiregulin from a urine sample.
[0038] In the present invention, the agent for specifically detecting amphiregulin may be characterized as an amphiregulin-specific antibody or aptamer, but is not limited thereto, and any agent capable of detecting the presence or absence of amphiregulin mRNA or protein from a urine sample or measuring the amount thereof may be used. In the examples of the present invention, an ELISA method using an amphiregulin-specific antibody is used, but a PCR method using a primer and / or a PNA probe for measuring the amount of amphiregulin mRNA may also be used.
[0039] In the present invention, the term "agent capable of specifically detecting amphiregulin" refers to a molecule that can be used to detect a marker by measuring the expression level of a biomarker (i.e., amphiregulin mRNA or protein) whose expression changes due to renal dysfunction. The expression level of the biomarker can be determined by confirming the expression level of the marker mRNA or protein.
[0040] In the present invention, the term "antibody" is a term known in the art and means a specific protein molecule directed against an antigenic site. For the purposes of the present invention, an antibody means an antibody that specifically binds to a biomarker protein of the present invention, and such an antibody may be produced by cloning each gene into an expression vector by a conventional method to obtain a protein encoded by the marker gene, and then producing the protein by a conventional method from the obtained protein. This also includes partial peptides that can be produced from the protein, and the partial peptides of the present invention contain at least 7 amino acids, preferably 9 amino acids, and more preferably 12 or more amino acids.
[0041] The form of the antibody of the present invention is not particularly limited, and includes polyclonal antibodies, monoclonal antibodies, and parts thereof as long as they have antigen-binding ability, and includes all immunoglobulin antibodies. Furthermore, the antibody of the present invention also includes special antibodies such as humanized antibodies.
[0042] The antibody used in the detection of the renal function diagnostic marker of the present invention includes a complete form having two full-length light chains and two full-length heavy chains, as well as a functional fragment of the antibody molecule. The functional fragment of the antibody molecule means a fragment that has at least an antigen-binding function, and includes Fab, F(ab'), F(ab')2, Fv, etc.
[0043] In the present invention, "measuring the expression level of a protein" refers to a process of confirming the presence or absence and the expression level of a marker protein for renal dysfunction in a biological sample of an individual in order to diagnose a renal disease, and for example, the amount of the protein can be confirmed by detecting an antigen-antibody complex using an antibody that specifically binds to the marker protein. Specific examples of analytical methods include, but are not limited to, Western blot, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket rabbit electrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, and protein chip.
[0044] In the present invention, "diagnosis" means to confirm the presence or characteristics of a pathological condition. For the purposes of the present invention, said diagnosis may be interpreted as confirming the presence or absence of renal disease.
[0045] In the present invention, a "diagnostic marker, a marker for diagnosis, or a diagnostic marker" refers to a substance that can distinguish a sample in which renal dysfunction has occurred or is likely to occur from a sample from a healthy individual, and a sample from an individual with renal dysfunction contains a polypeptide or nucleic acid (e.g., mRNA, etc.), or a protein in which the diagnostic marker (i.e., amphiregulin) shows an increase compared to a sample from a healthy individual.
[0046] Protein or gene information of the biomarker for diagnosing kidney disease provided by the present invention can be easily obtained using a known gene database. For example, the amino acid sequence of the biomarker protein amphiregulin is registered in the known gene database NCBI (National Center for Biotechnology Information) and is as follows:
[0047] SEQ ID NO:1 MRAPLLPPAPVVLSLLILGSGHYAAGLDLNDTYSGKREPFSGDHSADGFEVTSRSEMSSGSEISPVSEMPSSSEPSSGADYDYSEEYDNEPQIPGYIVDDSVRVEQVVKPPQNKTESENTSDKPKR KKKGGKNGKNRRNRKKKNPCNAEFQNFCIHGECKYIEHLEAVTCKCQQEYFGERCGEKSMKTHSMIDSSSLSKIALAAIAAFMSAVILTAVAVITVQLRRQYVRKYEGEAEERKKLRQENGNVHAIA
[0048] In the present invention, the amphiregulin may be characterized by being represented by the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
[0049] In the present invention, the kidney disease may be characterized as being selected from the group consisting of renal fibrosis, renal syndrome, kidney cancer, chronic renal failure, diabetic nephropathy, acute pyelonephritis, acute renal failure, end stage renal failure, hypertensive kidney disease, Reye's syndrome, gout, Sjogren's syndrome, Behcet's disease, lupus, candidiasis, hemorrhagic fever with renal syndrome, leptospirosis, Legionnaires' disease, autosomal dominant polycystic kidney disease, and hydronephrosis, but is not limited thereto.
[0050] In another aspect, the present invention relates to a kit for diagnosing kidney disease, comprising the composition.
[0051] The kit of the present invention can detect a marker by confirming the expression level of a marker protein for diagnosing kidney disease. The kit for diagnosing kidney disease of the present invention may include an antibody that selectively recognizes a marker for measuring the expression level of a marker for diagnosing kidney function, as well as one or more other component composition solutions or devices suitable for an analysis method.
[0052] As a specific example, the kit for measuring the expression level of a protein for diagnosing kidney disease in the present invention may include a substrate, a suitable buffer solution, a secondary antibody labeled with a chromogenic enzyme or a fluorescent substance, and a chromogenic substrate for immunological detection of an antibody. Here, the substrate may be a nitrocellulose membrane, a 96-well plate synthesized with a polyvinyl resin, a 96-well plate synthesized with a polystyrene resin, or a glass slide, the chromogenic enzyme may be peroxidase or alkaline phosphatase, the fluorescent substance may be FITC or RITC, and the chromogenic substrate may be ABTS (2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)), OPD (o-phenylenediamine), TMB (tetramethylbenzidine), or the like.
[0053] In the present invention, the kit may be characterized as being a protein chip kit or an immunodiagnostic kit, but is not limited thereto.
[0054] In yet another aspect, the present invention relates to a method for providing information for diagnosing a kidney disease, the method comprising the steps of: (a) obtaining a urine sample from an individual; (b) detecting amphiregulin in a urine sample; and (c) determining that the individual has kidney disease if amphiregulin detected in the urine sample is greater than or equal to 5 pg / mgCr.
[0055] In the present invention, when amphiregulin detected in a urine sample is 5 pg / mgCr or more, preferably 6 pg / mgCr or more, more preferably 6.3 pg / mgCr or more, and most preferably 6.5 pg / mgCr or more, the individual may be determined to have kidney disease.
[0056] In the present invention, the detection of amphiregulin may be characterized by being carried out by an amphiregulin-specific binding reaction using an amphiregulin-specific antibody or aptamer, but is not limited thereto.
[0057] In yet another aspect, the present invention provides a method for detecting amphiregulin in an individual's urine sample to provide the information necessary to diagnose kidney disease.
[0058] Specifically, gene expression can be detected at the protein level, and isolation of proteins from biological samples can be performed using known procedures.
[0059] In the present invention, the term "individual" refers to an animal having a kidney as a bodily organ among living organisms existing in a natural system, preferably a mammal, more preferably a human. Examples of the mammal include rodents (e.g., rats, mice, etc.), rabbits, horses, cows, sheep, dogs, cats, monkeys, and humans, but the types of individuals of the present invention are not limited to these examples.
[0060] In the present invention, samples for detecting amphiregulin include samples such as tissues, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid or urine in which the amphiregulin mRNA or protein expression levels differ between normal individuals and individuals with renal disease, with urine samples being preferred.
[0061] In the present invention, analytical methods for detecting marker proteins include, but are not limited to, Western blot, ELISA, radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket rabbit electrophoresis, tissue immunostaining, immunoprecipitation analysis, complement fixation analysis, FACS, protein chips, etc. These analytical methods can compare the amount of antigen-antibody complex formed in a normal control group with the amount of antigen-antibody complex formed in an individual suspected of kidney disease, and can determine whether or not there is a significant increase in the expression level of a protein in a marker gene for diagnosing kidney disease, thereby predicting or confirming the actual occurrence of kidney disease in an individual suspected of kidney disease. The antigen-antibody complex means a complex of a marker protein for diagnosing kidney disease and an antibody specific thereto, and the amount of antigen-antibody complex formed can be quantitatively measured based on the signal magnitude of a detection label.
[0062] The protein expression level measurement is preferably performed using the ELISA method. ELISA includes various ELISA methods such as direct ELISA using a labeled antibody that recognizes an antigen attached to a solid support, indirect ELISA using a labeled antibody that recognizes a capture antibody in a complex of an antibody that recognizes an antigen attached to a solid support, direct sandwich ELISA using a further labeled antibody that recognizes an antigen in a complex of an antibody and an antigen attached to a solid support, and indirect sandwich ELISA using a labeled secondary antibody that recognizes this antibody after reacting with a further antibody that recognizes the antigen in a complex of an antibody and an antigen attached to a solid support. More preferably, the detection is performed by a sandwich ELISA method in which an antibody is attached to a solid support and reacted with a sample, and then a labeled antibody that recognizes the antigen in the antigen-antibody complex is attached and enzymatically colored, or a labeled secondary antibody is attached to the antibody that recognizes the antigen in the antigen-antibody complex and enzymatically colored. The degree of complex formation between the kidney disease diagnostic marker protein and the antibody can be confirmed to determine whether or not kidney disease has occurred.
[0063] Also, preferably, Western blotting using one or more antibodies against the kidney disease diagnostic marker is used. For example, total protein is separated from a sample, electrophoresed to separate the proteins according to size, and then transferred to a nitrocellulose membrane to react with an antibody. The amount of protein generated by gene expression can be confirmed by a method of confirming the amount of generated antigen-antibody complex using a labeled antibody, thereby confirming the presence or absence of kidney function abnormality. The detection method is performed by examining the expression level of the marker gene in a control group and the expression level of the marker gene in cells in which kidney function abnormality has occurred. The protein level can be expressed as an absolute (e.g., μg / ml) or relative (e.g., relative signal intensity) difference of the above-mentioned marker protein.
[0064] In addition, preferably, a protein chip is used in which one or more antibodies against the kidney disease diagnostic markers are arranged at predetermined positions on a substrate and immobilized at high density. For example, a method of analyzing a sample using a protein chip involves isolating a protein from a sample, hybridizing the isolated protein with the protein chip to form an antigen-antibody complex, and reading the complex to confirm the presence or expression level of the protein, thereby confirming the occurrence of kidney dysfunction.
[0065] By using these detection methods, the protein expression level in a normal control group is compared with the gene expression level in an individual suspected of having kidney disease, thereby confirming or predicting the presence or absence of actual kidney function abnormality in a patient suspected of having kidney disease. That is, after measuring the expression level of the marker of the present invention from a urine sample of an individual suspected of having kidney disease and measuring the expression level of the marker of the present invention from a urine sample of a healthy individual and comparing the two, if it is confirmed that the expression level of the marker of the present invention is significantly increased compared to that of a healthy individual, the individual can be predicted to have kidney disease.
[0066] Meanwhile, according to the experimental results of the present inventors, it was confirmed that urinary amphiregulin reflects basal renal function well, can predict the degree of renal damage at the time of measurement, and can predict the progression of renal damage in the future as well as at the time of measurement by analysis using follow-up observation data. Measurement of urinary amphiregulin level can be used as a biomarker for predicting end-stage renal failure in patients with kidney disease.
[0067] Thus, in yet another aspect, the present invention provides a method for providing information for predicting the likelihood of progression to end stage renal disease, comprising the steps of: (a) collecting a urine sample from a patient suffering from kidney disease; (b) measuring the amount of amphiregulin in a urine sample; and (c) determining that the patient is at risk of progressing to end stage renal failure if the measured amount of amphiregulin is 30 pg / mgCr or greater.
[0068] In the present invention, when the measured amphiregulin amount is 30 pg / mgCr or more, preferably 35 pg / mgCr or more, more preferably 39 pg / mgCr or more, and most preferably 39.9 pg / mgCr or more, the patient may be determined to be at risk of progressing to end stage renal failure.
[0069] In the present invention, the patient suffering from a kidney disease may be characterized as being a patient with chronic renal failure, but is not limited thereto.
[0070] In the present invention, in step (c), the possibility of progression to end stage renal failure may be characterized by, but is not limited to, determining that the probability of progression to end stage renal failure within two years is 50%, preferably 60% or more by measuring urinary amphiregulin.
[0071] In yet another aspect, the present invention relates to the use of amphiregulin or a composition comprising an agent that specifically detects amphiregulin for diagnosing kidney disease.
[0072] In still another aspect, the present invention relates to use of an agent capable of specifically detecting amphiregulin for producing a reagent for diagnosing kidney disease.
[0073] In yet another aspect, the present invention relates to a method for diagnosing a kidney disease, comprising the steps of: (a) obtaining a urine sample from an individual; (b) detecting amphiregulin in a urine sample; and
[0074] (c) determining that the individual has kidney disease if amphiregulin detected in the urine sample is greater than or equal to 5 pg / mgCr.
[0075] In yet another aspect, the present invention relates to a method for predicting likelihood of progression to end stage renal disease, comprising the following steps: (a) collecting a urine sample from a patient suffering from kidney disease; (b) measuring the amount of amphiregulin in a urine sample; and (c) determining that the patient is at risk of progressing to end stage renal failure if the measured amount of amphiregulin is 30 pg / mgCr or greater.
[0076] The present invention will be described in more detail below with reference to examples. These examples are merely for the purpose of illustrating the present invention, and the scope of the present invention is not limited to these examples.
[0077] Example 1. Verification of amphiregulin expression in urine samples from pulmonary fibrosis animal models with normal renal function
[0078] In order to determine the presence or absence of abnormalities in renal function using urine samples from an animal model of pulmonary fibrosis, an experiment was carried out to detect amphiregulin in urine samples.
[0079] 1.1. Animal experiment methods
[0080] To create a pulmonary fibrosis animal model, 15 units of bleomycin (BLM) (B5507, Sigma, USA) stock was dissolved in 5 ml of PBS to make 3 units / ml, and 50 ul of the solution was administered to C57BL / 6 mice via intratracheal instillation at 1.5 units / kg of mouse body weight. After 14 days had passed since the creation of the pulmonary fibrosis animal model by bleomycin induction, the following parameters were measured: weight, urinary albumin / creatinine ratio, and serum creatinine. Furthermore, histological analysis was performed on lung and kidney tissues. To confirm whether fibrosis had occurred in lung and kidney tissues, fibronectin and collagen 1 were analyzed. Then, gene expression analysis was performed to determine the level of amphiregulin expression in each tissue.
[0081] 1.2 RNA isolation and expression analysis of fibrotic disease genes and amphiregulin genes
[0082] Lung and kidney tissues were obtained from the sacrificed mice and crushed using a homogenizer. Total RNA was extracted using an RNA extraction kit (AccuPrep Cell total RNA extraction kit, BIONEER, Korea). The extracted RNA was quantified at 1ug using a spectrophotometer. RNA reverse transcriptase (AccuPower® RocketScript TM RT Premix with o cDNA was prepared using ligo(dT)20 (Bioneer, Korea) according to the manufacturer's instructions. The prepared cDNA was used as a template for SYBR green real-time qPCR to analyze the relative expression rate of total mRNA in each group as follows. The prepared cDNA was diluted 5-fold with distilled water in each well of a 96-well plate, and 3 μl of the diluted cDNA was added to each well of an AccuPower® GreenStar TM A mixture was prepared by mixing 25 μl of 10 ...
[0083] [Table 1]
[0084] As a result, as shown in Figure 1, there was no difference in gene expression between bleomycin-induced mice and healthy mice in kidney tissue, but the difference in AREG was statistically significantly increased in bleomycin-induced mice in lung tissue. On the other hand, as shown in Figures 2 and 3, to confirm whether fibrosis had progressed in each tissue, collagen 1 and fibronectin, which are fibrotic disease markers, were examined. As a result, it was confirmed that there was no difference in expression of collagen 1 and fibronectin between healthy mice and bleomycin-induced mice in kidney tissue, but that in lung tissue, the expression levels of mice in which pulmonary fibrosis was induced by bleomycin were statistically significantly increased compared to healthy mice. Therefore, it was confirmed by gene expression analysis that fibrosis occurred only in lung tissue and that fibrosis was not induced in kidney tissue in bleomycin-induced lung fibrosis mice.
[0085] 1.3. Detection of Amphiregulin and Albumin / Creatinine Ratio in Urine Samples
[0086] 1-3-1. Mouse amphiregulin ELISA method
[0087] To detect amphiregulin in mouse urine, Mouse Amphiregulin Duoset ELISA (DY989, R&D systems, USA) was used. Mouse capture amphiregulin antibody (DY989, R&D systems, USA) was added to each well at a concentration of 800ng / ml and coated at 100ul per well. Then, 100ul of 1% BSA was added to each well and reacted at room temperature for 1 hour to remove non-specific reactions other than the sample-antibody reaction. Each well was washed three times with PBST containing 0.05% Tween20 as a washing buffer. Then, 100ul of mouse urine was added to each well of the coated 96-well plate and reacted at room temperature for 2 hours. After the reaction, the urine sample was removed from each well, and each well was washed three times with PBST containing 0.05% Tween20 as a washing buffer. Then, 100 ul of detection antibody (DY989, R&D systems, USA) was added to each well at a concentration of 25.0 ng / ml and reacted at room temperature for 2 hours. After the reaction, the detection antibody solution was removed and the wells were washed three times with PBST. Secondary antibody, Streptavidin-HRP (DY989, R&D systems, USA), was diluted at a ratio of 1:200 and added to each well at 100 ul, and reacted at room temperature for 20 minutes. After the reaction, each well was washed three times for 5 minutes each with PBST. Then, 100 ul of 1-step Ultra TMB (34028, Thermo, USA) was added to each well and reacted at room temperature. After that, 100 ul of sulfuric acid (H2SO4) was added to each well to stop the reaction, and the absorbance of each well was measured at a wavelength of 450 nm using a spectrophotometer. The quantitative values of each sample were calculated by creating an equation for the standard curve using the measured absorbance values. As a result, the amphiregulin / creatinine ratio corrected for creatinine values showed no significant difference between healthy mice and mice with pulmonary fibrosis induction, and it was confirmed that the urinary amphiregulin / creatinine values in the pulmonary fibrosis model with normal kidney function were not significantly different from those in healthy mice (Figure 4).
[0088] 1-3-2. Detection of albumin / creatinine ratio in mouse urine
[0089] The experiment was performed using an albumin ELISA kit (Excocell, Phila, PA19103, Cat:1011). To measure albumin, urine samples were diluted at a ratio of 1:13 with NHE buffer (Excocell, Phila, PA19103, Cat:1011) and 50 ul of each was added to each well. Then, 50 ul of primary antibody (Primary Ab) (Excocell, Phila, PA19103, Cat:1011) was added to each well and incubated at room temperature for 1 hour. After that, the wells were washed 10 times with distilled water, and 100 ul of two-color developer (Excocell, Phila, PA19103, Cat:1011) was added to each well and incubated at room temperature for 20 minutes. The reaction was stopped by adding 100 ul of two-color stopper (Excocell, Phila, PA19103, Cat: 1011) and the absorbance was measured at 450 nm using a spectrophotometer. The measured absorbance values were used to create a calculation formula for the standard curve and calculate the quantitative value of each sample.
[0090] The reason for measuring creatinine in urine is to correct for the fact that the amount of urine amphiregulin may vary from measurement to measurement depending on the concentration of urine. Therefore, a creatinine ELISA kit (Excocell, Phila, PA19103, Cat: 1012) was used to measure creatinine as follows. The urine sample was diluted 1:10 with distilled water and placed in each well. Then, a picrate solution (Excocell, Phila, PA19103, Cat: 1012) was prepared and placed in each well at 100 ul to react at room temperature. The absorbance was measured at 500 nm using a spectrophotometer, and then 100 ul of an acid reagent (Excocell, Phila, PA19103, Cat: 1012) was placed in each well and the absorbance was measured after 5 minutes. The final result was calculated by subtracting the secondary absorbance from the primary absorbance. A formula for the standard curve was created using the absorbance values measured for creatinine standard concentrations of 10 mg / dL, 3 mg / dL, and 1 mg / dL, and the quantitative values of each sample were calculated.
[0091] In addition, there was no significant difference in the albumin / creatinine ratio between mice with pulmonary fibrosis induction and healthy mice (Figure 5), indicating that renal function was maintained normally in mice with pulmonary fibrosis induction.
[0092] 1.4. Histopathological analysis
[0093] Immunohistochemical staining was performed on lung and kidney tissues in the animal models prepared above for histopathological verification. Each group of animal models was sacrificed, and paraffin sections were prepared through tissue fixation, washing, dehydration, clearing, infiltration, embedding, and thin sectioning. The paraffin sections were cut thinly with a thin sectioner, and the tissues were attached to slides. The attached tissues were deparaffinized, hydrated, washed, stained, dehydrated, cleared, mounted, and then stained with hematoxylin and eosin, and also stained with Masson's trichrome. Next, tissue staining was requested to the KPNT analysis facility.
[0094] As a result, it was found that more fibrotic cells were differentiated in the lung tissue of mice with pulmonary fibrosis induction than in healthy mice, and the expression level of collagen 1 was analyzed using MT staining, and it was confirmed that more collagen was deposited in the mice with pulmonary fibrosis induction than in healthy mice (Figure 6A). However, in the kidney tissue, no significant difference was observed between healthy mice and mice with pulmonary fibrosis induction, and similar tissue conditions were maintained, and collagen 1 deposition was not confirmed in the mice with pulmonary fibrosis induction (Figure 6B).
[0095] 1-5. Blood urea nitrogen and creatinine measurements
[0096] When kidney function deteriorates, substances excreted through the kidneys accumulate in the body, the most representative of which are BUN and creatinine, and the concentrations of these substances are known to closely reflect kidney function. Therefore, to confirm kidney function, blood urea nitrogen (BUN) and creatinine levels were measured in serum samples.
[0097] As shown in Figure 7, there was no statistically significant difference in blood urea nitrogen between bleomycin-induced mice and healthy mice. Also, as shown in Figure 8, there was no difference in creatinine between healthy mice and bleomycin-induced mice. Therefore, it was confirmed that the kidney function of the bleomycin-induced pulmonary fibrosis animal model was maintained normally.
[0098] Example 2. Verification of amphiregulin expression in serum and urine of patients who underwent kidney tissue examination
[0099] The amphiregulin concentration was measured by ELISA in the serum and urine of patients who underwent kidney tissue examination. Serum and urine amphiregulin expression was analyzed in patients with minor glomerular change, which has pathological findings similar to those of normal kidneys, and patients with IgA nephropathy and diabetic nephropathy, which have more advanced pathological findings. In addition, the results of kidney tissue examinations of these patients were examined, and they were divided into four groups according to the degree of histological findings related to renal fibrosis, and the level of amphiregulin expression in urine was compared between these groups.
[0100] 2-1. Amphiregulin analysis using ELISA in patient serum and urine samples
[0101] To detect amphiregulin in human serum or urine, Human Amphiregulin Duoset ELISA (DY262, R&D systems, USA) was used. Specifically, 100 ul of amphiregulin antibody was added to each well of a 96-well plate at a concentration of 2.00 ug / ml to coat it. Then, 100 ul of 1% BSA was added to each well and reacted at room temperature for 1 hour to suppress non-specific expression other than the sample-antibody reaction. Each well was washed three times with PBST containing 0.05% Tween 20 as a washing buffer. 100 ul of patient serum or urine raw solution sample was added to each well and reacted at room temperature for 2 hours, after which the serum or urine sample was removed from each well and each well was washed three times with PBST containing 0.05% Tween 20 as a washing buffer. Each well was washed three times with PBST, and 100 ul of detection antibody (DY262, R&D systems, USA) was added to each well at a concentration of 100 ng / ml, and reacted at room temperature for 2 hours. After that, the detection antibody solution was removed, and each well was washed three times with PBST, and 100 ul of streptavidin-HRP (DY262, R&D systems, USA) secondary antibody was diluted at a ratio of 1:200 and added to each well at room temperature for 20 minutes. After the reaction, each well was washed three times with PBST for 5 minutes each, and 100 ul of 1-step Ultra TMB (34028, Thermo, USA) was added to each well and reacted at room temperature. Then, 100 ul of sulfuric acid (H2SO4) was added to each well to stop the reaction. The absorbance of each well was measured at a wavelength of 450 nm using a spectrophotometer, and the quantitative value of each sample was calculated by constructing an equation for a standard curve using the measured absorbance values.
[0102] As a result, we found that there was no significant difference in serum amphiregulin expression among patients with minor glomerular changes, IgA nephropathy, and diabetic nephropathy, whereas urinary amphiregulin expression was increased in patients with IgA nephropathy and diabetic nephropathy, which have more severe renal pathological findings, compared to patients with minor glomerular changes (Figure 9).
[0103] Meanwhile, the patient group was compared according to the severity of histological findings related to renal fibrosis, and divided into groups of absent, mild, moderate, and severe fibrosis, and the concentration of amphiregulin was examined in urine samples from the patients. Urinary amphiregulin expression was significantly increased in patients with moderate stages of interstitial fibrosis and intimal thickening compared to patients with absent fibrosis. Urinary amphiregulin expression was significantly increased in patients with tubular atrophy and mesangial expansion compared to patients with absent fibrosis, in the moderate and severe stages. Therefore, it was found that the more severe the renal fibrosis in kidney tissue, the more the expression of urinary amphiregulin increased (Figure 10).
[0104] Based on the results of interstitial fibrosis, a representative scale reflecting renal fibrosis, from the tissue examination, patients were divided into two groups: patients with no renal fibrosis (no interstitial fibrosis observed) and patients with confirmed renal fibrosis (interstitial fibrosis observed), and a receiver operating characteristic (ROC) curve analysis was performed based on the urinary amphiregulin concentration. As a result, the optimal cutoff value of amphiregulin was derived to be 6.55 pg / mg, which is the value that maximizes the sum of sensitivity and specificity.
[0105] Thus, amphiregulin expression of 6.55 pg / mgCr or higher in an individual's urine sample confirmed progression of kidney disease, particularly renal fibrosis (sensitivity, 0.84; specificity, 0.78).
[0106] Example 3. Verification of amphiregulin expression in plasma and urine of diabetic patients
[0107] The amphiregulin expression patterns were examined in plasma and urine samples isolated from normal controls and type 2 diabetes patients. Since the severity of diabetic nephropathy in type 2 diabetes patients can be determined by the amount of albuminuria, these patients were divided into groups according to the level of albuminuria: normoalbuminuria, microalbuminuria, and macroalbuminuria, and the amphiregulin expression levels in plasma and urine were compared for each group. ELISA analysis was performed using the same method and product (DY262, R&D systems, USA) as described in Example 2-1.
[0108] As a result, as shown in Figure 11, there was no clear difference in plasma amphiregulin concentration between the normal control group and type 2 diabetes patients, and no significant difference in concentration was observed between the albuminuria groups. In contrast, urinary amphiregulin concentration was clearly increased in type 2 diabetes patients compared to the normal control group, and it was confirmed that urinary amphiregulin concentration also increased in type 2 diabetes patients as albuminuria became more severe, i.e., as the severity of diabetic nephropathy increased.
[0109] Amphiregulin-to-creatinine ratio values for the experimental groups were analyzed as follows:
[0110] [Table 2]
[0111] [Table 3]
[0112] Example 4. Verification of prediction of progression of end-stage renal failure using urinary amphiregulin concentration in a group of patients who underwent kidney tissue examination
[0113] Among the patients who underwent renal tissue examination, 72 patients who were diagnosed with minor glomerular change, IgA nephropathy, or diabetic nephropathy were included. Urinary amphiregulin was quantified using ELISA using urine samples taken at the time of tissue examination. The patients were then classified according to the stage of chronic renal failure while observing their prognosis. The classification of chronic renal failure was based on the KDIGO guidelines, one of the most representative guidelines for the diagnosis and treatment of chronic renal failure (Kidney Int Suppl 2012;2013:1-150).
[0114] The urinary amphiregulin concentration analyzed at the time of tissue examination according to the stage of chronic renal failure was graphed, and the patient group was divided into three groups according to the tertiles of urinary amphiregulin concentration (T1: 0.598-9.472 pg / mgCr, T2: 9.473-39.904 pg / mgCr, T3: 39.905-597.252 pg / mgCr). Kaplan-Meier survival analysis was performed to confirm whether there was a difference in the probability of progression to end-stage renal failure in the three groups. The ELISA analysis method was the same as that described in Example 2-1.
[0115] The results are shown in Figure 12. The chronic new disease in the group of patients who underwent renal tissue examination was distributed in stages 1 to 4, and the concentration of amphiregulin in urine was measured higher in patients in stages 3 to 4, whose renal function was deteriorated, compared with patients in stages 1 to 2, whose renal function was relatively good. In addition, as shown in Figure 13, the Kaplan-Meier survival curve showed that the incidence of end-stage renal failure was significantly higher in the T3 group, which showed high urinary amphiregulin concentrations in the tertiles of urinary amphiregulin concentrations at the time of tissue examination (ESRD incidence rate per 1000 person-years: T1, 0.0 [95% CI, 0.0-117.3]; T2, 71.4 [95% CI, 14.2-229.0]; T3, 600.0 [95% CI, 296.3-1095.1]).
[0116] On the other hand, to improve the accuracy of the experiment, adjustments were made for age, sex, baseline 24-hr urinary protein (creatine), and baseline GFR. When comparing the combined T1 / T2 group and the T3 group among the tertile groups, the progression rate of end-stage renal failure was significantly higher in the T3 group (hazard ratio between the T3 group and the T1 / T2 group: 11.7 [95% CI 1.6-86.5]). In addition, when urine amphiregulin (Log urine amphiregulin-to-creatinine ratio) was set as a continuous variable and analyzed, it was found to be significantly associated with the occurrence of chronic renal failure even after adjustment for these variables (hazard ratio: 5.1 [95% CI 1.814.8] for every 1 increase in Log urine amphiregulin-to-creatinine ratio). In the patient group that participated in this experiment, it was shown that when the urinary amphiregulin level was 39.905 pg / mgCr or more, the probability of developing end-stage renal failure two years later was 62.2% (see FIG. 13).
[0117] Although the specific parts of the present invention have been described in detail above, it will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents. [Industrial Applicability]
[0118] The present invention has an advantage that kidney disease, for which early diagnosis is important, can be easily diagnosed in a non-invasive manner using a urine sample, and also has an advantage that the application of the present invention to patients diagnosed with chronic renal failure can predict the possibility of progression to end-stage renal failure in advance.
Claims
1. A composition for diagnosing kidney disease, comprising an agent for specifically detecting amphiregulin or its mRNA.
2. The composition for diagnosing kidney disease according to claim 1, wherein the agent specifically detects amphiregulin in a urine sample.
3. The composition for diagnosing kidney disease according to claim 1 , wherein the amphiregulin is represented by the amino acid sequence of SEQ ID NO:
1.
4. The composition for diagnosing kidney diseases according to claim 1 , wherein the agent for specifically detecting amphiregulin is an amphiregulin-specific antibody or aptamer.
5. The composition for diagnosing kidney disease according to claim 1, characterized in that the kidney disease is selected from the group consisting of renal fibrosis, renal syndrome, kidney cancer, chronic renal failure, diabetic nephropathy, acute pyelonephritis, acute renal failure, end stage renal failure, hypertensive kidney disease, Reye's syndrome, gout, Sjogren's syndrome, Behcet's disease, lupus, candidiasis, hemorrhagic fever with renal syndrome, leptospirosis, Legionnaires' disease, autosomal dominant polycystic kidney disease and hydronephrosis.
6. A kit for diagnosing kidney disease, comprising the composition according to any one of claims 1 to 4.
7. The kit for diagnosing kidney disease according to claim 6, which is a protein chip kit or an immunodiagnostic kit.
8. The kidney disease diagnostic kit according to claim 6, characterized in that the kidney disease is selected from the group consisting of renal fibrosis, renal syndrome, kidney cancer, chronic renal failure, diabetic nephropathy, acute pyelonephritis, acute renal failure, end-stage renal failure, hypertensive kidney disease, Reye's syndrome, gout, Sjogren's syndrome, Behcet's disease, lupus, candidiasis, hemorrhagic fever with renal syndrome, leptospirosis, Legionnaires' disease, autosomal dominant polycystic kidney disease and hydronephrosis.
9. How to provide information for diagnosing kidney disease, including the following steps: (a) obtaining a urine sample from an individual; (b) detecting amphiregulin in a urine sample; and (c) determining that the individual has kidney disease if amphiregulin detected in the urine sample is greater than or equal to 5 pg / mgCr.
10. 10. The method for diagnosing kidney disease according to claim 9, wherein the detection of amphiregulin is carried out by an amphiregulin-specific reaction using an amphiregulin-specific antibody or aptamer.
11. The method for diagnosing kidney disease according to claim 9, characterized in that the kidney disease is selected from the group consisting of renal fibrosis, renal syndrome, kidney cancer, chronic renal failure, diabetic nephropathy, acute pyelonephritis, acute renal failure, end-stage renal failure, hypertensive kidney disease, Reye's syndrome, gout, Sjogren's syndrome, Behcet's disease, lupus, candidiasis, hemorrhagic fever with renal syndrome, leptospirosis, Legionnaires' disease, autosomal dominant polycystic kidney disease and hydronephrosis.
12. Providing information to predict the likelihood of progression to end-stage renal disease, including: (a) collecting a urine sample from a patient suffering from kidney disease; (b) measuring the amount of amphiregulin in a urine sample; and (c) determining that the patient is at risk of progressing to end stage renal failure if the measured amount of amphiregulin is 30 pg / mgCr or greater.
Citation Information
Patent Citations
Novel forms of amphiregulin, methods of making and using same, and compositions containing same
JP2000504206A
Methods and compositions for the diagnosis and prognosis of renal injury and renal failure
JP2014511122A
Molecule and chimeric molecules thereof
US20090155267A1
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20140147864A1
